Article Text

Download PDFPDF
Original research
ZNF142 mutation causes sex-dependent neurologic disorder
  1. Regina Proskorovski-Ohayon1,
  2. Marina Eskin-Schwartz1,2,
  3. Zamir Shorer3,
  4. Rotem Kadir1,
  5. Daniel Halperin1,
  6. Max Drabkin1,
  7. Yuval Yogev1,
  8. Sarit Aharoni1,
  9. Noam Hadar1,
  10. Hagit Cohen4,
  11. Ekaterina Eremenko1,
  12. Yonatan Perez1,
  13. Ohad S Birk1,2
  1. 1 The Morris Kahn Laboratory of Human Genetics and Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
  2. 2 Institute of Human Genetics, Soroka Medical Center, Beer Sheva, Israel
  3. 3 Soroka Medical Center, Beer Sheva, Israel
  4. 4 Department of Psychology, Ben-Gurion University of the Negev, Beer-Sheva, Israel
  1. Correspondence to Dr Ohad S Birk, Ben-Gurion University of the Negev, POB 151 Beer-Sheva 84101, Israel; obirk{at}bgu.ac.il

Abstract

Background Sex-specific predilection in neurological diseases caused by mutations in autosomal genes is a phenomenon whose molecular basis is poorly understood. We studied females of consanguineous Bedouin kindred presenting with severe global developmental delay and epilepsy.

Methods Linkage analysis, whole exome sequencing, generation of CRISPR/cas9 knock-in mice, mouse behaviour and molecular studies

Results Linkage analysis and whole exome sequencing studies of the affected kindred delineated a ~5 Mbp disease-associated chromosome 2q35 locus, containing a novel homozygous frameshift truncating mutation in ZNF142, in line with recent studies depicting similar ZNF142 putative loss-of-function human phenotypes with female preponderance. We generated knock-in mice with a truncating mutation adjacent to the human mutation in the mouse ortholog. Behaviour studies of homozygous Zfp142R1508* mice showed significant phenotype only in mutant females, with learning and memory deficits, hyperactivity and aberrant loss of fear of open spaces. Bone marrow and spleen of homozygous Zfp142R1508* mice showed depletion of lymphoid and haematopoietic cells, mostly in females. RT-PCR showed lower expression of Zpf142 in brain compartments of female versus male wild-type mice. RNA-seq studies of hippocampus, hypothalamus, cortex and cerebellum of female wild-type versus homozygous Zfp142R1508* mice demonstrated differentially expressed genes. Notably, expression of Taok1 in the cortex and of Mllt6 in the hippocampus was downregulated in homozygous Zfp142R1508* mice. Taok1 mutations have been associated with aberrant neurodevelopment and behaviour. Mllt6 expression is regulated by sex hormones and Mllt6 null-mutant mice present with haematopoietic, immune system and female-specific behaviour phenotypes.

Conclusion ZNF142 mutation downregulates Mllt6 and Taok1, causing a neurodevelopmental phenotype in humans and mice with female preponderance.

  • Epilepsy
  • Mutation
  • Genetics

Data availability statement

Data are available upon reasonable request. Data are available from the corresponding author upon reasonable request.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request. Data are available from the corresponding author upon reasonable request.

View Full Text

Footnotes

  • X @yogevyu, @OhadBirk

  • Contributors RP-S and OSB designed the studies. RP-S, ZS, DH, MD, YY, SA, NH, EE, YP collected data. RP-S, ME-S, RK, HG, YP, OSB analysed data. RP-S and OSB wrote the manuscript, approved by all authors. OSB is the guarantor of the manuscript.

  • Funding The research was funded by the Morris Kahn Family Foundation, the Israel Science Foundation (grants number 2034/18 and 2463/23) awarded to OSB and by the National Knowledge Center for Rare/Orphan Diseases sponsored by the Israel Ministry of Science, Technology and Space, at Ben-Gurion University of the Negev, Beer-Sheva, Israel.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer-reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.